WO2000070048A1 - Sequences de polynucleotides et de polypeptides codant un transporteur d'anion organique murin 6(moatp6) et methodes de depistage correspondantes - Google Patents

Sequences de polynucleotides et de polypeptides codant un transporteur d'anion organique murin 6(moatp6) et methodes de depistage correspondantes Download PDF

Info

Publication number
WO2000070048A1
WO2000070048A1 PCT/US2000/013316 US0013316W WO0070048A1 WO 2000070048 A1 WO2000070048 A1 WO 2000070048A1 US 0013316 W US0013316 W US 0013316W WO 0070048 A1 WO0070048 A1 WO 0070048A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
seq
polynucleotide
candidate compound
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/013316
Other languages
English (en)
Inventor
John Feild
Lin Yue
Harma Ellens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of WO2000070048A1 publication Critical patent/WO2000070048A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in identifying compounds that may be agonists and/or antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides Background of the Invention
  • the drug discover ⁇ ' process is currently undergoing a fundamental revolution as it embraces 'functional genomics', that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on 'positional cloning' A phenotype. that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
  • Multi-specific drug transporters are present in cells having a barrier function such as intestinal epithelial and brain microvessel endothehal cells. Other tissues, for example, liver and kidney, also contain multi-specific transporters that can mediate the excretion of drugs and metabolites. Information gained from using multi-specific transporters such as the mouse OATP6 gene product in cell-based, membrane-based binding or other assays could enhance drug formulation, selection of formulation excipients, and compound design
  • the present invention relates to mouse OATP6, in particular mouse OATP6 polypeptides and mouse OATP6 polynucleotides, recombinant materials and methods for their production.
  • the invention relates to methods for identifying agonists and antagonists/inhibitors of the mouse OATP6 gene.
  • This invention further relates to the generation of in vitro and in vivo comparison data relating to the polynucleotides and polypeptides in order to predict oral absorption and pharmacokinetics in man of compounds that either agonize or antagonize the biological activity of such polynucleotides or polypeptides
  • Such a comparison of data will enable the selection of drugs with optimal pharmacokinetics m man, i ⁇ ?., good oral bioavailabihty. blood-brain barrier penetration, plasma half life, and minimum drug interaction
  • the present invention further relates to methods for creating transgenic animals, which overexpress or underexpress or have regulatable expression of a mouse OATP6 gene and "knock-out" animals, preferably mice, in which an animal no longer expresses a mouse OATP6 gene. Furthermore, this invention relates to transgenic and knock-out animals obtained by using these methods. Such animal models are expected to provide valuable insight into the potential pharmacological and toxicological effects in humans of compounds that are discovered by the aforementioned screening methods as well as other methods.
  • the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with OATP6 imbalance in humans with the identified compounds
  • Another embodiment of this invention provides for methods to identify compounds that neither agonize nor antagonize OATP6.
  • This invention further relates to the generation of in vitro and in vivo comparison data to predict oral absorption and pharmacokinetics in man. Such a comparison of data will enable selection of drugs with optimal pharmacokinetics in man, i.e., good oral bioavailabihty, bram penetration, plasma half life, and minimum drug interaction
  • the present invention relates to mouse OATP6 polypeptides
  • polypeptides include isolated polypeptides comprising an ammo acid sequence having at least a 95% identity, most preferably at least a 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2.
  • polypeptides include those comprising the ammo acid of SEQ ID NO:2.
  • polypeptide sequence of SEQ ID NO.2 (e) the polypeptide sequence of SEQ ID NO.2; and (f) variants and fragments thereof; and portions of such polypeptides in (a) to (e) that generally contain at least 30 ammo acids, more preferably at least 50 ammo acids, thereof.
  • Polypeptides of the present invention are believed to be members of the organic anion transporter family of polypeptides. They are, therefore, of interest, because they can be used to establish assays to predict oral absorbtion and pharmacokinetics and thus enhance compound and formulation design. Furthermore, the polypeptides of the present invention can be used to establish assays to predict oral absorbtion and pharmacokinetics m man and thus enhance compound and formulation design, among others These properties, either alone or in the aggregate, are hereinafter referred to as "Mouse OATP6 activity” or “Mouse OATP6 polypeptide activity” or "biological activity of mouse OATP6.” Preferably, a polypeptide of the present invention exhibits at least one biological activity of Mouse OATP6.
  • Polypeptides of the present invention also includes variants of the aforementioned polypeptides, including alleles and splice va ⁇ ants.
  • Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative
  • Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 ammo acids are inserted, substituted, or deleted, in any combination.
  • Particularly preferred p ⁇ mers will have between 20 and 25 nucleotides.
  • Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an ammo acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous ammo acids from the ammo acid sequence of SEQ ID NO:2, or an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO:2.
  • biologically active fragments which are those fragments that mediate activities of mouse OATP6, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigemc or lmmunogenic in an animal, especially in a human. Particularly preferred are fragments comp ⁇ sing receptors or domams of enzymes that confer a function essential for viability of mouse or the ability to initiate, or maintain cause the Diseases m an particularly a human
  • Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis, therefore, these va ⁇ ants may be employed as intermediates for producing the full-length polypeptides of the invention
  • polypeptides of the present invention may be in the form of a "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional ammo acid sequence that contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance, multiple histidme residues, or an additional sequence for stability during recombinant production
  • the present invention also includes va ⁇ ants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative ammo acid substitutions, whereby a residue is substituted by another with like charactenstics.
  • Typical substitutions are among Ala, Val, Leu and He; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gin; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr.
  • Particularly preferred are va ⁇ ants in which several, 5-10, 1-5, 1-3, 1-2 or 1 ammo acids are substituted, deleted, or added in any combination
  • Polypeptides of the present invention can be prepared m any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombmantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods.
  • the present invention relates to Mouse OATP6 polynucleotides.
  • Such polynucleotides include isolated polynucleotides compnsmg a nucleotide sequence encoding a polypeptide having at least a 95% identity, to the ammo acid sequence of SEQ ID NO:2, over the entire length of SEQ ED NO:2.
  • polypeptides which have at least a 97% identity are highly preferred, while those with at least a 98-99% identity are more highly preferred, and those with at least a 99% identity are most highly preferred.
  • polynucleotides include a polynucleotide compnsmg the nucleotide sequence contained in SEQ ID NO- l encoding the polypeptide of SEQ ID NO:2.
  • Further polynucleotides of the present invention include isolated polynucleotides compnsmg a nucleotide sequence having at least a 95% identity, to a nucleotide sequence encoding a polypeptide of SEQ ED NO;2, over the entire coding region.
  • polynucleotides which have at least a 97% identity are highly preferred, while those with at least a 98-99% identity are more highly preferred, and those with at least a 99% identity are most highly preferred.
  • polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence having at least a 95% identity, to SEQ ED NO.1 over the entire length of SEQ ID NO.1.
  • polynucleotides which have at least a 97% identity are highly preferred, while those with at least a 98-99% identify are more highly preferred, and those with at least a 99% identity are most highly preferred.
  • Such polynucleotides include a polynucleotide compnsmg the polynucleotide of SEQ ID NO.1 , as well as the polynucleotide of SEQ ID NO.1
  • the invention also provides polynucleotides which are complementary to all the above described polynucleotides
  • the nucleotide sequence of SEQ ID NO 1 shows homology with rat LSTP (G.D Simonson, et al , J Cell Set. 107, 1065-1072, 1994).
  • the nucleotide sequence of SEQ ED NO: l is a cDNA sequence and comp ⁇ ses a polypeptide encoding sequence (nucleotide 19 to 1638) encoding a polypeptide of 540 ammo acids, the polypeptide of SEQ ID NO:2.
  • the nucleotide sequence encoding the polypeptide of SEQ ED NO:2 may be identical to the polypeptide encoding sequence of SEQ ED
  • polypeptide of SEQ ED NO:2 is structurally related to other proteins of the organic ion transporter family, having homology and/or structural similarity with rat LSTP (G.D. Simonson, et al , J Cell Sci. 107, 1065- 1072, 1994).
  • Preferred polypeptides and polynucleotides of the present invention are expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one mouse OATP6 activity.
  • Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library de ⁇ ved from mRNA in cells of mouse kidney and liver using the expressed sequence tag (EST) analysis (Adams, M.D., et al Science (1991) 252: 1651- 1656; Adams, M.D. et al .
  • EST expressed sequence tag
  • Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.
  • the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide m reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions.
  • a marker sequence that facilitates pu ⁇ fication of the fused polypeptide can be encoded.
  • the marker sequence is a hexa-histidme peptide. as provided in the pQE vector (Qiagen, Inc ) and described in Gentz, et al , Proc Natl Acad Sci USA (1989) 86.821-824, or is an HA tag.
  • the polynucleotide may also comprise non-coding 5' and 3' sequences, such as transcnbed, non-translated sequences, splicing and polyadenylation signals, ⁇ bosome binding sites and sequences that stabilize mRNA.
  • polypeptide vanants that comprise the ammo acid sequence of SEQ ED NO.2 and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 1 to 1 or 1 ammo acid residues are substituted, deleted or added, in any combination.
  • Particularly preferred probes will have between 30 and 50 nucleotides, but may have between 100 and 200 contiguous nucleotides of the polynucleotide of SEQ ED NO:l .
  • a preferred embodiment of the invention is a polynucleotide of consisting of or compnsmg nucleotide 19 to the nucleotide immediately upstream of or including nucleotide 1638 set forth in SEQ ID NO: 1 , both of which encode a mouse OATP6 polypeptide
  • the invention also includes a polynucleotide consisting of or compnsmg a polynucleotide of the formula:
  • X is hydrogen, a metal or a modified nucleotide residue, or together with Y defines a covalent bond, and at the 3' end of the molecule.
  • Ri and R3 are independently any nucleic acid residue or modified nucleic acid residue
  • m is an integer between 1 and 3000 or zero
  • n is an integer between 1 and 3000 or zero
  • R 2 is a nucleic acid sequence or modified nucleic acid sequence of the invention, particularly a nucleic acid sequence selected from SEQ ID NO: 1 or a modified nucleic acid sequence thereof.
  • R 2 is oriented so that its 5' end nucleic acid residue is at the left, bound to Ri and its 3' end nucleic acid residue is at the right, bound to R3.
  • any stretch of nucleic acid residues denoted by either Ri and/or R 2 , where m and/or n is greater than 1 may be either a heteropolymer or a homopolymer, preferably a heteropolymer
  • the polynucleotide of the abo ⁇ e formula is a closed, circular polynucleotide. which can be a double-stranded polynucleotide wherein the formula shows a first strand to hich the second strand is complementary.
  • m and/or n is an integer between 1 and 1000.
  • Other preferred embodiments of the invention are provided where m is an integer between 1 and 50, 100 or 500, and n is an integer between 1 and 50, 100. or 500.
  • Polynucleotides that are identical, or are substantially identical to a nucleotide sequence of SEQ ID NO: 1 may be used as hybridization probes for cDNA and genomic DNA or as pnmers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes
  • probes or pnmers will generally compnse at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides, and may even have at least 100 nucleotides. Particularly preferred pnmers will have between 20 and 25 nucleotides.
  • a polynucleotide encoding a polypeptide of the present invention may be obtained by a process compnsmg the steps of screening an approp ⁇ ate library under stringent hyb ⁇ dization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof, preferably of at least 15 nucleotides in length; and isolating full-length cDNA and genomic clones compnsmg said polynucleotide sequence.
  • stnngent hybndization conditions include overnight incubation at 42°C in a solution comprising- 50% formamide, 5xSSC (150mM NaCl, 15mM t ⁇ sodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in O.lx SSC at about 65°C.
  • 5xSSC 150mM NaCl, 15mM t ⁇ sodium citrate
  • 50 mM sodium phosphate pH7.6
  • 5x Denhardt's solution 10 % dextran sulfate
  • 20 microgram/ml denatured, sheared salmon sperm DNA followed by washing the filters in O.lx SSC at about 65°C.
  • the present invention also includes isolated polynucleotides, preferably of at least 100 nucleotides in length, obtained by screening an appropnate library under stnngent hybndization conditions with a labeled probe having the sequence of SEQ ED NO: 1 or a fragment thereof, preferably of at least 15 nucleotides
  • an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is cut short at the 5' end of the cDNA
  • primers designed to anneal withm the amplified product typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' m the known gene sequence
  • the products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer
  • Recombmant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems Accordingly, in a further aspect, the present invention relates to expression systems compnsmg a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombmant techniques Cell-free translation systems can also be employed to produce such proteins using RNAs denved from the DNA constructs of the present invention For recombmant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention Introduction of polynucleotides into host cells can be effected by methods descnbed in many standard laboratory manuals, such as Davis, et al , BASIC METHODS IN MOLECULAR BIOLOGY (1986) and Sambrook, et al .
  • Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, catiomc hpid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection
  • Representative examples of approp ⁇ ate hosts include bactenal cells, such as streptococci, staphylococci, E coll, Streptomyces and Bacillus subtihs cells: fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells A great vanety of expression systems can be
  • the expression systems may comprise control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used.
  • nucleotide sequence may be inserted into an expression system by any of a vanety of well-known and routine techniques, such as, for example, those set forth m Sambrook, et al., MOLECULAR CLONING, A LABORATORY
  • a polypeptide of the present invention is to be expressed for use m screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered
  • Polypeptides of the present invention can be recovered and punfied from recombmant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lect chromatography. Most preferably, high performance liquid chromatography is employed for punfication. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and/or purification
  • Mouse OATP6 gene products can be expressed m transgenic animals. Animals of any species, including, but not limited to: mice, rats, rabbits, guinea pigs, dogs, cats, pigs, micro-pigs, goats, and non-human pnmates, e.g., baboons, monkeys, chimpanzees, may be used to generate mouse OATP6 transgenic animals.
  • This invention further relates to a method of producing transgenic animals, preferably mouse, over-expressing mouse OATP6, which method may comprise the introduction of several copies of a segment compnsmg at least the polynucleotide sequence encoding SEQ ID NO:2 with a suitable promoter into the cells of a mouse embryo, or the cells of another species, at an early stage.
  • This invention further relates to a method of producing transgenic animals, preferably mouse, under-expressing or regulatably expressing mouse OATP6, which method may compnse the introduction of a weak promoter or a regulatable promoter (e.g..).
  • This invention also relates to transgenic animals, charactenzed m that they are obtained by a method, as defined above.
  • Any technique known in the art may be used to introduce a Mouse OATP6 transgene into animals to produce a founder line of animals.
  • Such techniques include, but are not limited to: pronuclear micromjection (U.S. Patent No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten, et al., Proc. Natl. Acad. Sci., USA 82: 6148-6152 (1985); gene targeting in embryonic stem cells (Thompson, et al , Cell 56: 313-321 (1989); electropolation of embryos (Lo, Mol. Cell Biol.
  • a further aspect of the present invention involves gene targeting by homologous recombination in embryonic stem cells to produce a transgenic animal with a mutation in a mouse
  • OATP6 gene (“knock-out” mutation).
  • knock-out animals there is mactivation of the mouse OATP6 gene or altered gene expression, such that the animals are useful to study the function of the mouse OATP6 gene, thus providing animals models of human disease, which are otherwise not readily available through spontaneous, chemical or irradiation mutagenesis.
  • Another aspect of the present invention involves the generation of so-called “knock-in” animals in which a portion of a wild-type gene is fused to the cDNA of a heterologous gene.
  • This invention further relates to a method of producing "knock-out" animals, preferably mice, no longer expressing mouse OATP6.
  • a mouse OATP6 cDNA SEQ ID NO: 1
  • SEQ ID NO: 1 can be used as a probe to screen suitable hbranes to obtain the munne OATP6 genomic DNA clone.
  • the method used to create a knockout mouse is charactenzed in that: a suitable mutation is produced m the polynucleotide sequence of the munne OATP6 genomic clone, which inhibits the expression of a gene encoding munne OATP6, or inhibits the activity of the gene product, said modified munne OATP6 polynucleotide is introduced into a homologous segment of munne genomic DNA, combined with an approp ⁇ ate marker, so as to obtain a labeled sequence compnsmg said modified munne genomic DNA, said modified munne genomic DNA compnsmg the modified polynucleotide is transfected into embryonic stem cells and correctly targeted events selected in vitro, then said stem cells are reinjected into a mouse embryo, then said embryo is implanted into a female recipient and brought to term as a chimera which transmits said mutation through the germhne. and homozygous recombmant mice are obtained at the
  • a mutation is generated in a munne OATP6 allele by the introduction of a DNA construct comprising DNA of a gene encoding munne OATP6, which munne gene contains the mutation
  • the mutation is targeted to the allele by way of the DNA construct
  • the DNA of the gene encoding munne OATP6 compnsed in the construct may be foreign to the species of which the recipient is a member, may be native to the species and foreign only to the individual recipient, may be a construct compnsed of synthetic or natural genetic components, or a mixture of these.
  • the mutation may constitute an insertion, deletion, substitution, or combination thereof
  • the DNA construct can be introduced into cells by, for example, calcium-phosphate DNA co-precipitation It is preferred that a mutation be introduced into cells using electroporation, micromjection, virus infection, hgand-DNA conjugation, virus-hgand-DNA conjugation, or hposomes
  • Another embodiment of the instant invention relates to "knock-out" animals, preferably mice, obtained by a method of producing recombmant mice as defined above, among others
  • Another aspect of this invention provides for in vitro mouse OATP6 "knock-outs", i e , tissue cultures
  • Animals of any species including, but not limited to- mice, rats, rabbits, guinea pigs, dogs, cats, pigs, micro-pigs, goats, and non-human p ⁇ mates, e g , baboons, monkeys, chimpanzees, may be used to generate in vitro mouse OATP6 "knock-outs”
  • Methods for "knocking out" genes in vitro are descnbed in Galh-Tahadoros, et al , Journal of Immunological Methods 181 1-15 (1995). Transgemc, "knock-m”.
  • mice and knock-out animals are a particularly advantageous model, from a physiological point of view, for studying Organic Anion Transporters.
  • Such animals will be valuable tools to study the functions of a mouse OATP6 gene
  • animal models are expected to provide information about potential toxicological effects in humans of any compounds discovered by an aforementioned screening method, among others
  • An understanding of how a Mouse OATP6 gene functions in these animal models is expected to provide an insight into treating and preventing human diseases including, but not limited to: cancer, inflammation, cardiovascular disease, central nervous system disorders, auto-immune disease, and kidney and liver disease.
  • Polypeptides of the present invention are responsible for many biological functions, including many disease states, m particular the Diseases mentioned herein It is, therefore, an aspect of the invention to devise screening methods to identify compounds that stimulate (agonists) or that inhibit (antagonists) the function of the polypeptide, such as agonists, antagonists and inhibitors. Accordingly, a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function of the polypeptide. In general, agonists or antagonists may be employed for therapeutic and prophylactic purposes for the Diseases mentioned herein mentioned. Compounds may be identified from a vanety of sources, for example, cells, cell- free preparations, chemical libraries, and natural product mixtures.
  • Such agonists and antagonists so- ldentified may be natural or modified substrates, hgands, receptors, enzymes, etc.. as the case may be, of the polypeptide; or may be structural or functional mimetics thereof (see Coligan, et al , CURRENT
  • the screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound.
  • a screening method may involve measuring or, qualitatively or quantitatively, detecting the competition of binding of a candidate compound to the polypeptide with a labeled competitor (e.g , agonist or antagonist).
  • screening methods may test whether the candidate compound results in a signal generated by an agonist or antagonist of the polypeptide, using detection systems appropriate to cells bearing the polypeptide.
  • Antagonists are generally assayed in the presence of a known agonist and an effect on activation by the agonist by the presence of the candidate compound is observed.
  • screening methods may simply comprise the steps of mixing a candidate compound with a solution comprising a polypeptide of the present invention, to form a mixture, measunng Mouse OATP6 activity in the mixture, and comparing a Mouse OATP6 activity of the mixture to a control mixture which contains no candidate compound
  • Polypeptides of the present may be employed m conventional low capacity screening methods and also m high-throughput screening (HTS) formats
  • HTS formats include not only the w ell-established use of 96- and, more recently, 384-well microtiter plates but also emerging methods such as the nanowell method described by Schullek et al Anal Biochem , 246, 20-29, (1997)
  • Fusion proteins such as those made from Fc portion and Mouse OATP6 polypeptide, as herein described, can also be used for high-throughput screening assays to identify antagonists of antagonists of the polypeptide of the present invention (see D Bennett et al J Mol Recognition, 8 52-58 (1995), and K Johanson, et al J Bwl Chem , 270(16) 9459-9471 (1995))
  • potential polypeptide antagonists include antibodies or, some cases, ohgopeptides or proteins that are closely related to ligands, substrates receptors enzymes, etc as the case may be, of a mouse OATP6 polypeptide, e g , a fragment of a ligand, substrate, receptor, enzyme, etc , or small molecules which bind to a mouse OATP6 polypeptide but do not elicit a response, so that an activity of a mouse OATP6 polypeptide is prevented
  • the present invention relates to a screening kit for identifying agonists, antagonist
  • polypeptide of the present invention (c) a cell membrane expressing a polypeptide of the present invention, which polypeptide is preferably that of SEQ ED NO 2
  • kits may comprise a substantial component
  • a polypeptide of the present invention may also be used m a method for the structure-based design of an agonist, antagonist or inhibitor of the polypeptide, by
  • Organic anion transporters such as OATP6, are present in cells having a barrier function, such as intestinal epithelial cells, bram microvessel endothehal cells, kidney epithelial cells, and liver hepatocytes It was recently recognized that these transporters contribute to poor intestinal absorption, poor penetration into the bram, rapid plasma clearance and ⁇ a ⁇ ability, as well as drug interactions
  • the present invention relates to the use of Mouse OATP6 polypeptides, polynucleotides, and recombmant materials thereof in selection screens to identify compounds which are neither agonists nor antagonist/inhibitors of Mouse OATP6 The data from such a selection screen is expected to provide in vitro and in vivo comparisons and to predict oral absorption, pharmacokinetics in humans.
  • Allele refers to one or more alternative forms of a gene occurring at a given locus in the genome.
  • “Fragment” of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide
  • “Fragment” of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence of SEQ ED NO 1
  • Fusion protein refers to a protein encoded by two, often unrelated, fused genes or fragments thereof
  • EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulm molecules together with another human protein or part thereof
  • employing an immunoglobulm Fc region as a part of a fusion protein is advantageous for use m therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e g , EP-A 0232 262]
  • “Homolog” is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined Falling within this generic term are the terms, “ortholog”, and “paralog” “Ortholog” refers to polynucleotides/genes or polypeptide that are homologs via speciation, that is closely related and assumed to have commend descent based on structural and functional considerations "Paralog” refers to polynucleotides/genes or polypeptide that are homologs via gene duplication, for instance, duplicated variants within a genome
  • Identity reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences
  • identity refers to an exact nucleotide to nucleotide or ammo acid to ammo acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.
  • a "% identity” may be determined.
  • the two sequences to be compared are aligned to give a maximum correlation between the sequences.
  • a % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length
  • Similarity is a further, more sophisticated measure of the relationship between two polypeptide sequences
  • similarity means a comparison between the ammo acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated 'score' from which the "% similarity" of the two sequences can then be determined
  • BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length. the program assuming that the shorter sequence represents a portion of the longer. In comparison,
  • GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Neddleman and Wunsch (J Mo I Bwl . 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length
  • the parameters "Gap Weight” and “Length Weight” used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively.
  • % identities and similanties are determined when the two sequences being compared are optimally aligned
  • NCBI National Center for Biotechnology Information
  • NCBI National Center for Biotechnology Information
  • FASTA Pearson W R and Lipman D.J., Proc Nat Acad Sci USA, 85: 2444-2448 (1988) (available as part of the Wisconsin Sequence Analysis Package).
  • BLOSUM62 amino acid substitution matrix Hemkoff S. and Henikoff J.G.
  • the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a polynucleotide or a polypeptide sequence of the present invention, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.
  • a polynucleotide sequence having, for example, at least 95% identity to a reference polynucleotide sequence is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference sequence.
  • Such point mutations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion.
  • point mutations may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
  • a polynucleotide sequence having at least 95% identity to a reference polynucleotide sequence up to 5% of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described.
  • a polypeptide sequence having, for example, at least 95% identity to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include up to five point mutations per each 100 ammo acids of the reference sequence.
  • Such point mutations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These point mutations may occur at the ammo- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the ammo acids m the reference sequence or in one or more contiguous groups within the reference sequence.
  • a sequence polypeptide sequence having at least 95% identity to a reference polypeptide sequence up to 5% of the ammo acids of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described.
  • % identities such as 96%, 97%, 98%, 99%, and 100%.
  • Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 95, 97 or 100% identity to the reference sequence of SEQ ED NO: 1 , wherein said polynucleotide sequence may be identical to the reference sequence of SEQ ED
  • nucleotide NO:l may include up to a certain integer number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides m the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO: l by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleotides in SEQ ID NO: l, or
  • n n is the number of nucleotide alterations
  • x n is the total number of nucleotides m SEQ ED NO: l
  • y ⁇ s 0.95 for 95%, 0.97 for 97% or 1.00 for 100%
  • • is the symbol for the multiplication operator
  • any non-mteger product of x n and y is rounded down to the nearest integer prior to subtracting it from x n
  • Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ED NO:2 may create nonsense, missense or frameshift mutations m this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.
  • Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide having at least a 95, 97 or 100% identity to a polypeptide reference sequence of SEQ ID NO:2, wherein said polypeptide sequence may be identical to the reference sequence of SEQ ED NO:2 or may include up to a certain integer number of ammo acid alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one ammo acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the ammo acids m the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of amino acid alterations is determined by multiplying the total number of amino acids in SEQ ED NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of ammo acids in SEQ ID NO
  • n a is the number of amino acid alterations
  • x a is the total number of ammo acids in SEQ ID NO:2
  • y is 0.95 for 95%, 0.97 for 97% or 1.00 for 100%
  • • is the symbol for the multiplication operator
  • any non-mteger product of x a and y is rounded down to the nearest integer pnor to subtracting it from x a
  • Isolated means altered "by the hand of man" from its natural state, i e , if it occurs in nature, it has been changed or removed from its original environment, or both
  • a polynucleotide or a polypeptide naturally present in a living organism is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting matenals of its natural state is “isolated", as the term is employed herein
  • “Knock-m” refers to the fusion of a portion of a wild-type gene to the cDNA of a heterologous gene
  • “Knock-out” refers to partial or complete suppression of the expression of a protein encoded by an endogenous DNA sequence in a cell
  • the “knock-out” can be affected by targeted deletion of the whole or part of a gene encoding a protein, in an embryonic stem cell As a result the deletion may prevent or reduce the expression of the protein m any cell in the whole animal m which it is normally expressed
  • “Splice Variant” as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of mtrons, which results in the production of more than one mRNA molecule each of that may encode different ammo acid sequences
  • Transgenic animal refers to an animal to which exogenous DNA has been introduced while the animal is still in its embryonic stage
  • the transgenic approach aims at specific modifications of the genome, e g , by introducing whole transc ⁇ ptional units into the genome, or by up- or down-regulating pre-existing cellular genes
  • the targeted character of certain of these procedures sets transgenic technologies apart from experimental methods in which random mutations are conferred to the germlme, such as administration of chemical mutagens or treatment with ionizing solution
  • Polynucleotide generally refers to any polynbonucleotide or polydeox ⁇ bonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA
  • Polynucleotides include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double- stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double- stranded regions, hybrid molecules comprising DNA and RNA that may be smgle-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions
  • polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA
  • the term “polynucleotide” also includes DNAs or RNAs comprising one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons "Modified" bases include, for example
  • polynucleotide embraces chemically, enzymatically or metabohcally modified forms of polynucleotides as typically found m nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells "Polynucleotide” also embraces relatively short polynucleotides, often referred to as ohgonucleotides
  • Polypeptide refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i e , peptide isosteres.
  • Polypeptide refers to both short chains, commonly referred to as peptides, ohgopeptides or oligomers, and to longer chains, generally referred to as proteins Polypeptides may comprise ammo acids other than the 20 gene-encoded ammo acids.
  • Polypeptides include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art.
  • Modifications may occur anywhere in a polypeptide, including the peptide backbone, the ammo acid side-chams and the ammo or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may comprise many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods.
  • Modifications include acetylation, acylation, ADP- ⁇ bosylation, amidation, covalent attachment of flavm, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a hpid or lipid derivative, covalent attachment of phosphotidylinositol, cross-lmkmg, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteme, formation of pyroglutamate, formylation, gamma- carboxylation, glycosylation, GPI anchor formation, hydroxylation, lodination, methylation, my ⁇ stoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of ammo acids to proteins such as arginylation, and ubiquitination (see, for instance,
  • Variant refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties.
  • a typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the ammo acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result m ammo acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
  • a typical variant of a polypeptide differs m ammo acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, m many regions, identical.
  • a variant and reference polypeptide may differ in ammo acid sequence by one or more substitutions, additions, deletions m any combination.
  • a substituted or inserted ammo acid residue may or may not be one encoded by the genetic code.
  • a variant of a polynucleotide or polypeptide may be a naturally occurring such as an allehc variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des polypeptides et des polynucléotides OATP6 de souris et une méthode de production de tels polypeptides au moyen de techniques de recombinaison. Cette invention concerne également des méthodes de dépistage de composés qui ont des effets agonistes ou antagonistes sur l'OATP6 de la souris. On attend de tels composés qu'ils soient utiles au traitement de maladies humaines, y compris, mais pas exclucivement: du cancer, des inflammations, des maladies cardiovasculaires, des troubles liés au système nerveux central, des maladies auto-immunes, et des maladies hépatiques et rénales.
PCT/US2000/013316 1999-05-14 2000-05-15 Sequences de polynucleotides et de polypeptides codant un transporteur d'anion organique murin 6(moatp6) et methodes de depistage correspondantes Ceased WO2000070048A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13413799P 1999-05-14 1999-05-14
US60/134,137 1999-05-14
US57029300A 2000-05-12 2000-05-12
US09/570,293 2000-05-12

Publications (1)

Publication Number Publication Date
WO2000070048A1 true WO2000070048A1 (fr) 2000-11-23

Family

ID=26832006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013316 Ceased WO2000070048A1 (fr) 1999-05-14 2000-05-15 Sequences de polynucleotides et de polypeptides codant un transporteur d'anion organique murin 6(moatp6) et methodes de depistage correspondantes

Country Status (1)

Country Link
WO (1) WO2000070048A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1173457A4 (fr) * 1999-03-04 2005-08-03 Smithkline Beecham Corp Sequences de polynucleotides et de polypeptides codant pour le transporteur de l'anion organique 6(hoatp6) et procede de criblage associe

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053064A1 (fr) * 1997-05-23 1998-11-26 Tanabe Seiyaku Co., Ltd. Transporteur d'anions organiques et gene codant pour ce dernier
WO1999013072A1 (fr) * 1997-09-08 1999-03-18 Chugai Research Institute For Molecular Medicine, Inc. Genes transporteurs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053064A1 (fr) * 1997-05-23 1998-11-26 Tanabe Seiyaku Co., Ltd. Transporteur d'anions organiques et gene codant pour ce dernier
WO1999013072A1 (fr) * 1997-09-08 1999-03-18 Chugai Research Institute For Molecular Medicine, Inc. Genes transporteurs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1173457A4 (fr) * 1999-03-04 2005-08-03 Smithkline Beecham Corp Sequences de polynucleotides et de polypeptides codant pour le transporteur de l'anion organique 6(hoatp6) et procede de criblage associe

Similar Documents

Publication Publication Date Title
US6358725B1 (en) Mouse aspartic secretase-1 (mASP1)
US6361975B1 (en) Mouse aspartic secretase-2(mASP-2)
US6169166B1 (en) Polynucleotide and polypeptide sequences encoding rat mdr1b2 and screening methods thereof
WO2000049170A1 (fr) RECEPTEUR 11cby MURIN
US6420544B1 (en) Polynucleotide and polypeptide sequences encoding murine organic anion transporter 5 (mOATP5)
WO2000070048A1 (fr) Sequences de polynucleotides et de polypeptides codant un transporteur d'anion organique murin 6(moatp6) et methodes de depistage correspondantes
US6432678B1 (en) Macaca cynomolgus IL 18
WO2000070033A1 (fr) Htra2 murin
EP1173483A1 (fr) Acrp30r1m, homologue d'acrp30
US20020055128A1 (en) Polynucleotide and polypeptide sequences encoding rat mdr1a and screening methods thereof
US20020160492A1 (en) Bovine aggrecanase-1
WO2000061785A2 (fr) Sequences polynucleotidiques et polypeptidiques de cathepsine k de singe
WO2001032889A1 (fr) Serine/threonine kinase murine yak3
WO2000071583A1 (fr) Homologue de l'interleukine 1 murine, il-1h3
EP1165608A1 (fr) Membre de la famille frzb, frazzled
WO2001010889A1 (fr) Brs3 du rat a recepteurs couples par des proteines g
US6355465B1 (en) Compounds
US20020058323A1 (en) Monkey urotensin II
EP1144440A2 (fr) Nouveaux composes
WO1999051634A1 (fr) Proteine humaine beta 3 a jonction lacunaire
WO2000077180A1 (fr) Reductase
WO2001040304A1 (fr) Récepteur d'orexine 2 de singe
WO2001049744A1 (fr) Recepteur de mas couple a la proteine g de la souris
WO2001040252A1 (fr) Récepteur de singe sensible au calcium
US20020064852A1 (en) Murine serine/threonine kinase, mDYRK2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP